Pevonedistat | Friends of Cancer Research

You are here

Pevonedistat

Sponsor: 
Takeda Pharmaceutical Company
Indication: 
Treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS)
Category: 
Year: 
2020
Date: 
Jul 30th
FDA Status: 
Designation Granted